Alexander Eggermont

Professor of Immunotherapy at UMCU, Utrecht University, and CSO at Princess Máxima Center, the Netherlands. He is the past Director General of Gustave Roussy Cancer Institute, France (2010-2019) and Emeritus Professor of Oncology at University Paris-Saclay, and Emeritus Professor of Surgical Oncology at Erasmus University Rotterdam.

In Germany he is Board Member of the Comprehensive Cancer Center Munich of Technical University Munich&Ludwig Maximiliaan University, and Coordinator of the Comprehensive Cancer Center Program of the Deutsche KrebsHilfe,

Professor Eggermont is a melanoma specialist and immunotherapy development specialist. He trained at the Surgery Branch of the NCI (Steve Rosenberg) with a PhD in Tumor Immunology. He was the PI on multiple adjuvant immunotherapy trials in melanoma: FDA approvals in 2009 (Peg-IFN), 2015 (ipilimumab) and pembrolizumab (2019). Also TNF-isolated limb perfusion EMA approval in 1998 for advanced sarcomas of the extremities.

Scientific Output: > 1000 publications. H-index/citations: 139 / >100.000 citations

Leading positions of professional societies: President EACS European Academy Cancer Sciences (2010-2019), President Cancer Core Europe (2014-1019), President ECCO (2009-2011), President EORTC (2006-2009), Board of ASCO (2008-2010), ESMO executive board (2014-2018). Editor-in-Chief of European Journal of Cancer (2011-)

Selection awards: Joseph Maisin Chair in Oncology at Catholic University of Leuven (2001); ASCO Statemans Award (2010); Michiel Van Vloten Award of Dutch Surgical Society (2016); John Wayne Award of Clinical Research of Society Surgical Oncology (2018); Doctorate Honoris Causa (University Essen, Germany) (2018); Honorary Professor KAZIOR (Kazakh Institute of Oncology and Radiotherapy)(2019); Deutsche Krebshilfe Cancer Award (2020)

Societal Awards

• Légion d’Honneur, France (2015)